One To Watch

AskBio

Company Overview

A fully integrated adeno-associated virus gene therapy company, AskBio is advancing one-time treatments for heart failure, Parkinson's disease, and limb-girdle muscular dystrophy as a wholly owned subsidiary of Bayer AG. Formally named Asklepios BioPharmaceutical Inc, the company operates independently under Bayer's ownership, which is unusual for a fully integrated subsidiary at this scale. Its pipeline spans three clinical-stage programs, each targeting diseases where durable, single-administration therapy could displace chronic management.

Headquarters and Global Presence

AskBio is based in Research Triangle Park, North Carolina. Its reach extends well beyond the United States: GenePHIT, its Phase II heart failure trial, runs across 46 sites in Austria, Germany, the Netherlands, Spain, the United Kingdom, and the US, while REGENERATE-PD enrolls patients in Germany, Poland, the United Kingdom, and the United States. The company's manufacturing subsidiary Viralgen supplies commercial-scale AAV drug product for clinical trials, and its EU-based subsidiary BrainVectis holds European Commission orphan drug designations for select programs.

Founding and History

Bayer AG acquired Asklepios BioPharmaceutical on 26 October 2020 for $2 billion upfront, with up to $2 billion in success-based milestone payments, citing the company's potential to anchor Bayer's cell and gene therapy strategy. The acquisition was notable: Bayer had long favored licensing over large acquisitions, making the price a statement of confidence in AskBio's AAV platform and what internal Bayer commentary described as an "IND machine." Gustavo Pesquin became CEO effective March 11, 2024, and Katherine High joined in the newly created role of president, therapeutics, also joining the board of directors, in a notable leadership realignment.

Therapy Areas and Focus

AskBio's primary focus is genetic and molecular drivers of disease where a one-time gene transfer could produce lasting correction. In cardiovascular medicine, it targets heart failure with reduced ejection fraction, a condition with high morbidity and limited curative options. In neurology, it targets Parkinson's disease and limb-girdle muscular dystrophy type 2I/R9, both areas of significant unmet need where existing therapies manage symptoms without addressing underlying pathology.

Technology Platforms and Modalities

All three clinical programs use adeno-associated virus vectors to deliver therapeutic genes in a single administration. The approach is designed to produce durable protein expression, avoiding the compliance and tolerability challenges of lifelong pharmacotherapy. AskBio has also signed a multi-year research collaboration and option agreement with ReCode Therapeutics to explore gene editing and nonviral delivery, suggesting the platform is expanding beyond classical AAV. A restructured joint venture with Touchlight gives both parties co-exclusive rights to supply the AAV market with doggybone DNA, a synthetic alternative to plasmid-based AAV manufacturing inputs.

Key Pipeline and Programs

Umiposgene parvec (AB-1002, also known as NAN-101) is AskBio's lead cardiovascular asset, an AAV gene therapy intended to promote expression of a constitutively active form of protein inhibitor 1 (I-1c), thereby blocking protein phosphatase 1, which is implicated in congestive heart failure. It is being evaluated in GenePHIT, a Phase II adaptive, double-blinded, placebo-controlled, randomized trial at 46 sites across six countries in heart failure with reduced ejection fraction, administered once by antegrade intracoronary artery infusion. Phase I 12-month data were published in Nature Medicine and presented at the European Society of Cardiology Heart Failure meeting; FDA granted Fast Track designation in April 2024.

AB-1005 (formerly AAV2-GDNF) delivers glial cell line-derived neurotrophic factor bilaterally to the putamen in Parkinson's disease, with a goal of slowing neurodegeneration. Its Phase Ib trial met its primary safety objective; complete results were published in Movement Disorders and presented at the American Academy of Neurology in April 2024, with no attributed serious adverse events through 18 months. The REGENERATE-PD Phase II trial (approximately 87 participants, sites in Germany, Poland, the UK, and the US) randomized its first US patient in January 2025 and first European patient in September 2025, making it the first neurosurgical gene therapy program for Parkinson's to enroll from both regions in a single Phase II. AB-1005 holds FDA Fast Track, RMAT (granted February 2025), and MHRA Innovation Passport designations, as well as Pioneering Regenerative Medical Product designation in Japan.

AB-1003 targets limb-girdle muscular dystrophy type 2I/R9 by delivering the FKRP gene preferentially to muscle tissue. The Phase I/II LION-CS101 trial dosed its first patient on 3 August 2023; initial safety data from the first cohort were presented in October 2025. AB-1003 holds FDA rare pediatric disease and orphan drug designations (both granted November 2024) and European Commission orphan drug designation via BrainVectis.

Recent Developments

On 31 August 2026, AskBio announced presentation of baseline participant characteristics from GenePHIT, describing it as one of the largest randomized gene therapy trials in heart failure to date. GenePHIT enrollment had closed on 1 April 2026, positioning the program for a results readout the following year. In September 2025, REGENERATE-PD became the first neurosurgical Parkinson's gene therapy program to randomize patients from both the United States and Europe in a single Phase II trial. In October 2024, AskBio entered a strategic collaboration with China's Belief BioMed to explore new gene therapy opportunities.

Key Personnel

Gustavo Pesquin serves as chief executive officer, having taken the role effective March 11, 2024. Katherine High, a widely recognized figure in gene therapy, joined as president, therapeutics, also serving on the board of directors, following the same 2024 leadership realignment. A new chief scientific officer was also appointed in June 2024, completing a substantial refresh of AskBio's executive team under Bayer's continued ownership.

Strategic Partnerships

AskBio operates within Bayer AG's cell and gene therapy strategy, with Bayer providing the financial and regulatory infrastructure supporting its independent operations. In October 2024, AskBio signed a strategic collaboration with Belief BioMed to explore new gene therapy programs. A multi-year research collaboration and option agreement with ReCode Therapeutics covers gene editing and nonviral delivery modalities. The restructured joint venture with Touchlight provides co-exclusive rights for both parties to supply doggybone DNA to the AAV market, addressing a key manufacturing input.

FAQ Section

Heart failure with reduced ejection fraction affects millions of patients whose options are limited to chronic drug regimens and devices. AskBio's thesis is that a single administration correcting a specific molecular defect, protein phosphatase 1 overactivity, can produce a durable therapeutic effect that pills and implants cannot. GenePHIT is one of the largest randomized gene therapy trials ever run in this indication, which signals how seriously the field is taking the hypothesis.

Protein phosphatase 1 is overactive in failing hearts and impairs calcium handling in cardiac muscle cells. AB-1002 delivers a gene encoding a constitutively active form of protein inhibitor 1 (I-1c), which blocks protein phosphatase 1 and is intended to restore more normal contractile function. Phase I data published in Nature Medicine showed the approach was sufficiently promising to support the large, blinded Phase II program now underway.

REGENERATE-PD is the first neurosurgical gene therapy trial for Parkinson's to enroll patients from both the United States and Europe within a single Phase II study, a logistical and regulatory achievement that matters for eventual regulatory submissions across jurisdictions. AB-1005 delivers GDNF directly to the putamen bilaterally in a one-time procedure, targeting neurodegeneration rather than symptom relief. Its RMAT designation, granted in February 2025, gives AskBio expedited FDA interaction that smaller Parkinson's gene therapy programs typically lack.

GenePHIT completed enrollment on 1 April 2026, with the last of its participants randomized across 46 sites in six countries. It is a Phase II adaptive, double-blinded, placebo-controlled trial, meaning interim analyses are possible as data mature.

The three active clinical programs cover cardiovascular disease (AB-1002 in heart failure with reduced ejection fraction), neurology (AB-1005 in Parkinson's disease and a completed Phase I enrollment in multiple system atrophy), and rare neuromuscular disease (AB-1003 in limb-girdle muscular dystrophy type 2I/R9). Both AB-1002 and AB-1005 hold Pioneering Regenerative Medical Product designation in Japan, signaling regulatory ambition beyond the US and Europe. The ReCode collaboration and Belief BioMed partnership indicate further pipeline expansion is planned.

AskBio has two programs in Phase II: GenePHIT (AB-1002, heart failure, enrollment complete) and REGENERATE-PD (AB-1005, Parkinson's, actively enrolling approximately 87 participants). AB-1003 is in Phase I/II in limb-girdle muscular dystrophy, with initial safety data from the first cohort reported in October 2025. The company is therefore simultaneously running its most advanced cardiovascular and neurological programs in controlled, randomized settings, a clinical footprint that reflects Bayer's substantial resource commitment.

Bayer acquired AskBio on 26 October 2020 for $2 billion upfront and up to $2 billion in success-based milestone payments, and the two have since taken regulatory milestones to market together, including FDA Fast Track designation for the AB-1002 heart failure program. The practical effect reads as capacity rather than direction. AskBio's own subsidiary Viralgen supplies commercial-scale drug product for the REGENERATE-PD Phase II trial, so the company controls manufacturing at the point where most gene therapy developers are still buying it in, and that is the constraint that usually decides whether an AAV program reaches a randomized trial at all.

Want to Update your Company's Profile?